Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial

Authors

Institutions

Publication Details

Journal
European Journal of Heart Failure
Published
2025-04-13
DOI
https://doi.org/10.1002/ejhf.3661
Citations
7
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
9.72

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial

Brian Lee Claggett, Pardeep S. Jhund, John J.V. McMurray, Alasdair Henderson et al.
7 citations
European Journal of Heart Failure
Heart Failure Treatment and Management
9.72
article

Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial

Brian Lee Claggett, Pardeep S. Jhund, John J.V. McMurray, Alasdair Henderson, Jawad H. Butt, Faiez M. Zannad, Muthiah Vaduganathan, Carolyn S.P. Lam, Bertram Pitt, Katharina Mueller, Adriaan A. Voors, Sanjiv J. Shah, Akshay S. Desai, Scott D Solomon, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni
article en
7 citations

Abstract

No abstract available for this paper.
European Journal of Heart FailureVol. 27(8)
Northwestern University (US), Brigham and Women's Hospital (US), Harvard University (US), Bayer (United States) (US), National University of Singapore (SG), University of Groningen (NL), University of Michigan (US), British Heart Foundation (GB), Ospedale Papa Giovanni XXIII (IT), National University Heart Centre Singapore (SG), National Heart Centre Singapore (SG), Bay Medical Center (US), University of Milano-Bicocca (IT), Bayer (Germany) (DE), University of Glasgow (GB), Université de Lorraine (FR)
Amgen, Eli Lilly and Company, AstraZeneca, Bayer, Sanofi, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Boston Scientific Corporation, Regeneron Pharmaceuticals, Cytokinetics, Sarepta Therapeutics, Fresenius Medical Care North America, MyoKardia, Impulse Dynamics, Moderna, British Heart Foundation, University of Glasgow, Daiichi-Sankyo, Novo Nordisk, Idorsia Pharmaceuticals, Intas Pharmaceuticals, National Institutes of Health, Chugai Pharmaceutical, Sanofi Pasteur, American Regent, Respicardia, Relypsa, National Heart, Lung, and Blood Institute
Openalex Percentile: Top 2%
Heart Failure Treatment and Management
9.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.